Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT01159210
First received: July 8, 2010
Last updated: September 13, 2012
Last verified: September 2012

July 8, 2010
September 13, 2012
July 2010
April 2012   (final data collection date for primary outcome measure)
Proportion of subjects who achieve normalisation of International normalised ratio (INR) to <= 1.3 within 30 (±5) minutes post administration of Prothromplex Total [ Time Frame: within 35 minutes after administration of study drug ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01159210 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
An International, Multi-centre, Prospective, Open-Label, Non-Randomised, Uncontrolled Study to Assess the Efficacy and Safety of Prothromplex Total in Oral Anticoagulant Reversal in Patients With Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X)

The purpose of the study is to assess the efficacy and safety of Prothromplex Total as a treatment for the immediate reversal of oral anticoagulant therapy with vitamin K antagonists in patients with acquired deficiency of prothrombin complex coagulation factors (II, VII, IX, X). Upon enrolment, subjects will receive Prothromplex Total for the treatment of acute bleeding due to oral anticoagulants or for the prevention of excessive bleeding during the interventional procedure (Day 1). Additional doses of Prothromplex Total may be administered at the discretion of the investigator. Efficacy and safety assessments will be performed during a period of 72 (± 4) hours after administration of the last dose of Prothromplex Total or until discharge from hospital, whichever occurs first.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prothrombin Complex Factor Deficiency
Biological: Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)
Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
Other Name: Prothromplex Total
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
61
June 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is at least 16 years or older at enrolment with acquired deficiency of prothrombin complex coagulation factors (II, VII, IX, X), due to oral anticoagulation with vitamin K antagonists (e.g. coumarin, warfarin), requiring reversal of oral anticoagulation for urgent surgery, or invasive procedure or acute bleeding episode
  • Subject or parent/legally authorised representative has provided written informed consent
  • Subject has INR >= 2,0 at screening
  • Subject is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

  • Subject has laboratory and/or clinical symptoms which are clearly indicative of overt disseminated intravascular coagulation (DIC)
  • Subject has been treated with whole blood, fresh frozen plasma (FFP), or platelets within 6 hours prior to study enrolment
  • Subject has a hypersensitivity to prothrombin complex concentrate (PCC) constituents (including heparin-induced thrombocytopenia)
  • Subject has blood loss of >= 5 units of blood
  • Subject has hereditary thrombophilia or bleeding disorder
  • Subject has a life expectancy of < 3 months
  • Subject has been on oral anticoagulant treatment for a period of < 4 weeks for the treatment of a thrombotic event such as deep vein thrombosis or pulmonary embolism
  • Subject has an acute ischemic cardiovascular disorder
  • Subject has or is suspected to have sepsis
  • Subject with acute or chronic liver failure (hepatic cirrhosis Child-PUGH score C)
  • Subject has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrolment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Hungary,   Austria
 
NCT01159210
220901
No
Baxter Healthcare Corporation
Baxter Healthcare Corporation
Not Provided
Study Director: Neil Inhaber, MD Baxter Healthcare Corporation
Baxter Healthcare Corporation
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP